SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MCHM transdermal gel drug delivery -- Ignore unavailable to you. Want to Upgrade?


To: EyeDrMike who wrote (379)6/5/1998 10:06:00 AM
From: esterina  Respond to of 419
 
from briefing.com

09:53 ET VIVUS Inc (VVUS) 7 1/8 +13/16 (+13%): Company says additional new data on the efficacy of MUSE in
clinical practice are scheduled for presentation at the American Diabetes Association meeting to be held June 13-16.
Company also scheduled to appear on CNBC Monday morning. See press release for specifics of VVUS' arguement.

shorts will cover now.



To: EyeDrMike who wrote (379)6/5/1998 10:57:00 AM
From: regine  Read Replies (1) | Respond to of 419
 
A SMALL CO. LIKE MCHM AND ESPECIALLY A BIOTECH CO.IS ALWAYS IN HOPE OF A BUYOUT, MOST BIOTECHS DO NOT HAVE THE FUNDS THEMSELVES, BUT THIS ONE MCHM DOES HAVE 25 MILLION CASH, NO DEBTS AND MULTIPLE NEGOTIATIONS
WITH LARGER COMPANIES COMING UP!

THOSE ARE THE POSITIVE POINTS YOU SEEM TO HAVE "FORGOTTEN"? smile
NOT TO MENTION THAT THEIR PHASE 1 AND 2 WERE 80% SUCCESSFUL AND WERE GIVEN THE OK TO GO ON FOR THE PHASE 3..

regine